Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Safety monitoring with ocular anti-vascular endothelial growth factor therapies.

Fung AE, Bhisitkul RB.

Br J Ophthalmol. 2008 Dec;92(12):1573-4. doi: 10.1136/bjo.2008.137604. No abstract available.

PMID:
19029158
2.

VEGF inhibitors for AMD and diabetic macular edema.

[No authors listed]

Med Lett Drugs Ther. 2015 Mar 16;57(1464):41-2. Review. No abstract available.

PMID:
25758545
3.
5.

Pegaptanib octasodium for the treatment of diabetic macular edema.

Schartman JP, Coney JM, Hornik JH, Miller DG.

Expert Opin Pharmacother. 2011 Jun;12(8):1317-1323. doi: 10.1517/14656566.2011.579902. No abstract available.

PMID:
21548719
7.

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.

Fong AH, Lai TY.

Clin Interv Aging. 2013;8:467-83. doi: 10.2147/CIA.S36811. Epub 2013 Apr 29. Review.

8.

Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema.

Giuliari GP, Guel DA, Gonzalez VH.

Curr Diabetes Rev. 2009 Feb;5(1):33-8. Review.

PMID:
19199896
9.

Anti-VEGF therapeutic approaches for diabetic macular edema.

Khurana RN, Do DV, Nguyen QD.

Int Ophthalmol Clin. 2009 Spring;49(2):109-19. doi: 10.1097/IIO.0b013e31819fd8b5. No abstract available.

PMID:
19349791
10.

Inhibitors of ocular neovascularization: promises and potential problems.

van Wijngaarden P, Coster DJ, Williams KA.

JAMA. 2005 Mar 23;293(12):1509-13. Review. No abstract available.

PMID:
15784876
11.

[Considerations about intravitreal triamcinolone use].

Gómez-Ulla F, López Gálvez MI.

Arch Soc Esp Oftalmol. 2007 Jun;82(6):327-9. Spanish. No abstract available.

12.

[Anti-VEGF: one drug for different conditions?].

Cohen SY, Massin P, Souied E.

J Fr Ophtalmol. 2013 Jan;36(1):2-4. doi: 10.1016/j.jfo.2012.11.001. Epub 2013 Jan 3. French. No abstract available.

13.

Paracentesis before intravitreal injection of bevacizumab.

Tsui YP, Chiang CC, Tsai YY.

Can J Ophthalmol. 2008 Apr;43(2):239; author reply 239-40. doi: 10.3129/i08-033. No abstract available.

PMID:
18347632
14.

Future Perspectives: Agents on the Horizon.

Maya JR, Sadiq MA, Agarwal A, Kaiser PK, Stoller GL, Sepah YJ, Nguyen QD.

Dev Ophthalmol. 2016;55:391-8. doi: 10.1159/000439037. Epub 2015 Oct 26. Review.

PMID:
26501694
15.

Monitoring ocular drug therapy by analysis of aqueous samples.

Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R, Arron JR.

Ophthalmology. 2009 Nov;116(11):2158-64. doi: 10.1016/j.ophtha.2009.04.038. Epub 2009 Aug 22.

PMID:
19700195
16.

Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

Agarwal A, Parriott J, Demirel S, Argo C, Sepah YJ, Do DV, Nguyen QD.

Expert Opin Pharmacother. 2015;16(17):2625-35. doi: 10.1517/14656566.2015.1100172. Epub 2015 Nov 2. Review.

PMID:
26523670
17.

[Antiangiogenesis therapy of age-related macular degeneration].

Sjølie AK, Mortensen KK, Hansen MH.

Ugeskr Laeger. 2005 Aug 29;167(35):3267. Danish. No abstract available.

PMID:
16138964
18.

Vascular endothelial growth factor Trap-Eye for diabetic macular oedema.

Kaiser PK.

Br J Ophthalmol. 2009 Feb;93(2):135-6. doi: 10.1136/bjo.2008.144071. No abstract available.

PMID:
19174397
19.

Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.

Tatlipinar S, Dinç UA, Yenerel NM, Görgün E.

Clin Exp Optom. 2012 Jan;95(1):94-8. doi: 10.1111/j.1444-0938.2011.00662.x. Epub 2011 Sep 28.

20.

Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes.

El-Shazly SF, El-Bradey MH, Tameesh MK.

Clin Exp Ophthalmol. 2014 May-Jun;42(4):369-78. doi: 10.1111/ceo.12182. Epub 2013 Sep 24.

PMID:
23927080

Supplemental Content

Support Center